Infinity Pharmaceuticals (NASDAQ:INFI) Receives Daily Media Sentiment Rating of 0.17

Media stories about Infinity Pharmaceuticals (NASDAQ:INFI) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Infinity Pharmaceuticals earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 44.1953091407541 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news articles that may have effected Accern Sentiment’s analysis:

Several equities research analysts recently issued reports on INFI shares. ValuEngine downgraded Infinity Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Zacks Investment Research raised Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 17th. Finally, Wells Fargo & Co raised Infinity Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Thursday, October 12th.

Shares of Infinity Pharmaceuticals (INFI) opened at $2.00 on Thursday. Infinity Pharmaceuticals has a one year low of $0.93 and a one year high of $3.84. The firm has a market capitalization of $101.38, a PE ratio of -1.75 and a beta of 2.82.

Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.06. The business had revenue of $6.00 million for the quarter, compared to the consensus estimate of $14.70 million. Infinity Pharmaceuticals had a negative return on equity of 50.76% and a negative net margin of 118.40%. During the same period last year, the business earned ($0.39) EPS. sell-side analysts predict that Infinity Pharmaceuticals will post -0.93 EPS for the current year.

In other news, President Lawrence E. Bloch acquired 500,000 shares of the firm’s stock in a transaction dated Wednesday, December 6th. The shares were bought at an average price of $1.81 per share, with a total value of $905,000.00. Following the acquisition, the president now owns 580,944 shares of the company’s stock, valued at $1,051,508.64. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.81% of the stock is currently owned by company insiders.

WARNING: This article was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/11/infinity-pharmaceuticals-infi-given-media-impact-score-of-0-17.html.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.

Insider Buying and Selling by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply